Francis W. Mullery serves as President and Chief Executive Officer of the ImprimisRx Division at HARROW INC., a leading eyecare pharmaceutical company. In this role, he drives the strategic vision, operational excellence, and growth of ImprimisRx, the nation's largest compounded pharmaceutical facility dedicated to ophthalmology and other specialty medications. Under his leadership, the division has expanded its portfolio of patient-specific compounded drugs, enhanced manufacturing capabilities to meet FDA standards, and solidified partnerships with eyecare professionals nationwide, positioning ImprimisRx as an innovator in affordable, accessible therapies. With over 30 years of experience in the pharmaceutical and healthcare industries, Mr. Mullery brings a proven track record of building high-performing teams and scaling operations. Prior to joining ImprimisRx in 2018, he held senior executive positions, including President of Akorn Pharmaceuticals' Injectables Division, where he oversaw the development and commercialization of critical care and ophthalmic products, achieving significant revenue growth and regulatory milestones. His earlier career included leadership roles at Bausch + Lomb and other industry leaders, focusing on sales, marketing, and supply chain optimization. Mr. Mullery's achievements include spearheading multiple successful product launches, navigating complex regulatory landscapes, and fostering innovation in compounding pharmacy. At HARROW INC., he continues to champion cost-effective alternatives to branded drugs, improving patient outcomes and provider satisfaction while advancing the company's mission to transform eyecare through compounded solutions.